A detailed history of Entropy Technologies, LP transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Entropy Technologies, LP holds 30,859 shares of TGTX stock, worth $1.04 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
30,859
Previous 8,780 251.47%
Holding current value
$1.04 Million
Previous $264 Million 360.41%
% of portfolio
0.12%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025

BUY
$27.67 - $42.99 $610,925 - $949,176
22,079 Added 251.47%
30,859 $1.22 Billion
Q4 2024

Jan 28, 2025

SELL
$21.31 - $35.09 $477,770 - $786,717
-22,420 Reduced 71.86%
8,780 $264 Million
Q3 2024

Nov 04, 2024

BUY
$17.21 - $25.28 $536,952 - $788,736
31,200 New
31,200 $730 Million
Q1 2024

May 08, 2024

BUY
$13.02 - $21.3 $325,929 - $533,202
25,033 Added 86.51%
53,969 $821 Million
Q4 2023

Feb 14, 2024

BUY
$6.68 - $18.81 $193,292 - $544,286
28,936 New
28,936 $494 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.88B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Entropy Technologies, LP Portfolio

Follow Entropy Technologies, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Entropy Technologies, LP, based on Form 13F filings with the SEC.

News

Stay updated on Entropy Technologies, LP with notifications on news.